← Back to Search

Imaging Device

HyperSight Imaging arm for Lung Cancer

N/A
Waitlist Available
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 of radiation treatment, day 2 of radiation treatment, and the last day of radiation treatment (up to 6 weeks after the start of treatment).
Awards & highlights

Summary

This trial aims to study a new imaging technology called HyperSight used on cancer patients during radiation treatment. The goal is to assess the quality of the images produced and how easy it is to use the

Who is the study for?
This trial is for individuals with lung, abdominal, head and neck, or pelvic cancers who are undergoing radiation treatment. Participants must be able to receive imaging on a specific machine (TrueBeam). The exact eligibility criteria aren't provided here.
What is being tested?
The study is testing the image quality of HyperSight Imaging technology when used during radiation therapy sessions on a TrueBeam linear accelerator. It's a single-group study focusing on how well this new imaging tech works in practice.
What are the potential side effects?
Since this trial focuses on evaluating imaging technology rather than medication or invasive procedures, side effects are not the main concern. However, typical risks associated with additional exposure to diagnostic imaging may apply.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 of radiation treatment, day 2 of radiation treatment, and the last day of radiation treatment (up to 6 weeks after the start of treatment).
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 of radiation treatment, day 2 of radiation treatment, and the last day of radiation treatment (up to 6 weeks after the start of treatment). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comparison of overall free-breathing image quality: HyperSight CBCT vs Conventional CBCT
Secondary study objectives
Breath hold imaging time
Comparison of Hounsfield Unit accuracy: HyperSight CBCT vs Conventional CBCT and CT Simulation images
Comparison of metal artifacts: HyperSight CBCT vs. Conventional CBCT
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging armExperimental Treatment1 Intervention
Subjects have both HyperSight and conventional CBCT imaging.

Find a Location

Who is running the clinical trial?

Varian, a Siemens Healthineers CompanyLead Sponsor
31 Previous Clinical Trials
7,253 Total Patients Enrolled
~31 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top